Takeda Uses Fine Tooth Comb To Find Inefficiencies After Poor Results

The belt-tightening has already hit Takeda’s oncology arm, leading to the exit of Deborah Dunsire, chief executive officer at Millennium: The Takeda Oncology Co.

TOKYO – Takeda Pharmaceutical Co. Ltd. fell far short of its financial year guidance and forecasts for the next year disappointed analysts. The dismal figures were attributed to higher-than-expected expenditures, and the company released details of a plan to rein in costs through 2017 to improve margins.

“At last year’s earnings meeting, I told you I see light at the end of the tunnel. One year later,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Japan

More from Focus On Asia